David Wolinsky, MD

Appointed
2011

Education & Fellowships

Fellowship - Saint Luke's/Roosevelt Hospital Center
Cardiovascular Disease
New York, NY USA
1983

Residency - Saint Luke's/Roosevelt Hospital Center
Internal Medicine
New York, NY USA
1981

Internship - Saint Luke's/Roosevelt Hospital Center
Internal Medicine
New York, NY USA
1979

Medical Education - Columbia University College of Physicians & Surgeons at Harlem Hospital Center
New York, NY USA
1978

Undergraduate - Columbia University
New York, NY USA

Professional Highlights

• Member of Board of Directors-American Society Nuclear Cardiology 2009 to present.
• Development heart failure transitional care program St. Peters Hospital -2009 -2011.
• Founder of "A Pair of Hearts"-cardiovascular risk reduction program for women .
• Lead author Model LCD for payment and appropriate utilization of nuclear cardiology procedures-2011.
• Past-President American Society Nuclear Cardiology
• Chair Health Policy Committee , American Society of Nuclear Cardiology
• Chair Health Policy Committee Florida Chapter American C\ollege of Cardiology

Certifications

• Nuclear Cardiology
• Internal Medicine - Cardiovascular Disease
• Internal Medicine

Specialty Interests

Nuclear cardiology, Cardiac Amyloidosis ,Congestive heart failure, Cardiac prevention, Cardiac Risk Assessment clinical cardiology, congestive heart failure, valvular heart disease

Awards & Honors

• Brian J. McGovern M.D. Excellence in Education Award- 2003.
• America's Top Doctors- Castle Connelly -2011

Memberships

• American College of Cardiology
• American Society of Nuclear Cardiology
• American Heart Assn.

See publications for David Wolinsky, MD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 8/19/2023, Dr. Wolinsky has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Wolinsky receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

• Astellas Pharma US, Inc.
• Pfizer, Inc.
• Alnylam Pharmaceuticals, Inc.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.